25 years of research put RIPK1 in the clinic. (January 2021)

• Record Type: Journal Article
• Authors: Liu, Lin; Lalaoui, Najoua
• Is Part Of: Seminars in cell & developmental biology. Volume 109(2021)
• Page Start: 86
• Page End: 95
• Publication Date: 2021-01
• Subjects: Bcl-2 B-cell lymphoma 2 -- cFLIP cellular FLICE inhibitory protein -- cIAP cellular inhibitor of apoptosis -- COSMIC catalogue of somatic mutations in cancer -- CRIA cleavage-resistant autoinflammatory syndrome -- CYLD cylindromatosis -- DAMP damage-associated molecular pattern -- DD death domain -- DNA deoxyribonucleic acid -- FADD Fas-associated protein with a death domain -- IBD inflammatory bowel disease -- IEC intestinal epithelial cell -- IFN interferon -- IKK IκB kinase -- IL interleukin -- LPS lipopolysaccharide -- LUBAC linear ubiquitin chain assembly complex -- MAPK mitogen-activated protein kinase -- MK2 MAPK-activated protein kinase 2 -- MLKL mixed lineage kinase domain-like -- NAP1 NAK-associated protein 1 -- NEMO NF-κB essential modulator -- NF-κB nuclear factor-kappa B -- PRR pattern recognition receptors -- RHIM RIP homotypic interaction motif -- RIG-1 retinoic acid-inducible gene I -- RIPK receptor-interacting protein kinase -- Sharpin SHANK-associated RH domain-interacting protein -- SIRS systemic inflammatory response syndrome -- Smac second mitochondria-derived activator of caspases (DIABLO) -- TAB TAK1 binding protein -- TAK1 transforming growth factor-β-activated kinase 1 -- TANK TRAF Family Member Associated NF-κB Activator -- TBK1 TANK Binding Kinase -- TEN toxic epidermal necrolysis -- TLR toll-like receptor -- TNF tumour necrosis factor -- TNFAIP3 tumour necrosis factor-α-induced protein 3 -- TNFR tumour necrosis factor receptor -- TRADD TNFR1-associated death domain protein -- TRAF2 TNF receptor-associated factor 2 -- TRIF TIR-domain-containing adapter-inducing interferon-β -- UBA ubiquitin-associated -- Yop Yersinia outer protein -- XIAP X-linked inhibitor of apoptosis protein -- ZBP1 Z-DNA binding protein 1; RIPK1 -- TNF -- PRR -- Apoptosis -- Necroptosis -- Inflammation -- Cancer; Cytology -- Periodicals; Developmental biology -- Periodicals; 571.6
• DOI: 10.1016/j.semcdb.2020.08.007
• Languages: English
• ISSNs: 1084-9521

Abstract

Abstract: Receptor Interacting Protein Kinase 1 (RIPK1) is a key regulator of inflammation. To warrant cell survival and appropriate immune responses, RIPK1 is post-translationally regulated by ubiquitylations, phosphorylations and caspase-8-mediated cleavage. Dysregulations of these post-translational modifications switch on the pro-death function of RIPK1 and can cause inflammatory diseases in humans. Conversely, activation of RIPK1 cytotoxicity can be advantageous for cancer treatment. Small molecules targeting RIPK1 are under development for the treatment of cancer, inflammatory and neurogenerative disorders. We will discuss the molecular mechanisms controlling the functions of RIPK1, its pathologic role in humans and the therapeutic opportunities in targeting RIPK1, specifically in the context of inflammatory diseases and cancers.